High-dose lymphoablative therapy (HDLT) with or without stem-cell rescue for treatment of severe autoimmune diseases
BlueCross BlueShield Association
Record ID 32003000728
English
Authors' objectives:
This Assessment summarizes published evidence from pilot studies and phase I/II trials of high-dose lymphoablative therapy with or without autologous stem-cell rescue for the treatment of severe autoimmune disease to determine the procedures effect on health outcomes.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Autoimmune Diseases
- Hematopoietic Stem Cell Transplantation
- Immunosuppressive Agents
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.